These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21675101)

  • 1. Razor blades, heparin and protamine--a potent mix.
    Quirke M; O'Donnell JJ
    Ir Med J; 2011 Apr; 104(4):126. PubMed ID: 21675101
    [No Abstract]   [Full Text] [Related]  

  • 2. Emergent pediatric anticoagulation reversal using a 4-factor prothrombin complex concentrate.
    Adams CB; Vollman KE; Leventhal EL; Acquisto NM
    Am J Emerg Med; 2016 Jun; 34(6):1182.e1-2. PubMed ID: 26652577
    [No Abstract]   [Full Text] [Related]  

  • 3. Antagonism of SR 90107A/Org 31540-induced bleeding by protamine sulfate in rats and mice.
    Bernat A; Hoffmann P; Herbert JM
    Thromb Haemost; 1996 Nov; 76(5):715-9. PubMed ID: 8950779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of enoxaparine-induced bleeding by protamine sulfate.
    Van Ryn-McKenna J; Cai L; Ofosu FA; Hirsh J; Buchanan MR
    Thromb Haemost; 1990 Apr; 63(2):271-4. PubMed ID: 2163553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice.
    Swieton J; Miklosz J; Yusa SI; Szczubialka K; Pawlak D; Mogielnicki A; Kalaska B
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incomplete reversal of enoxaparin toxicity by protamine: implications of renal insufficiency, obesity, and low molecular weight heparin sulfate content.
    Chawla LS; Moore G; Seneff MG
    Obes Surg; 2004 May; 14(5):695-8. PubMed ID: 15186641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of protamine hollow-fiber device for extracorporeal heparin removal.
    Liang JF; Emregul E; Yang VC
    Blood Purif; 2004; 22(2):198-202. PubMed ID: 15044818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protamine sulfate: crouching clot or hidden hemorrhage?
    Nielsen VG; Malayaman SN
    Anesth Analg; 2010 Sep; 111(3):593-4. PubMed ID: 20733163
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of protamine to rapidly reverse anticoagulant effect of unfractionated heparin in patients undergoing percutaneous coronary intervention.
    Patel AA; White CM; Coleman CI
    Conn Med; 2007 Feb; 71(2):93-5. PubMed ID: 17393902
    [No Abstract]   [Full Text] [Related]  

  • 10. The toxicology of heparin reversal with protamine: past, present and future.
    Sokolowska E; Kalaska B; Miklosz J; Mogielnicki A
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):897-909. PubMed ID: 27223896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intentional overdose with tinzaparin: management dilemmas.
    Balla I; Karafotias I; Christopoulos C
    J Emerg Med; 2014 Feb; 46(2):197-201. PubMed ID: 24084058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, controlled trial of individualized heparin and protamine management in infants undergoing cardiac surgery with cardiopulmonary bypass.
    Gruenwald CE; Manlhiot C; Chan AK; Crawford-Lean L; Foreman C; Holtby HM; Van Arsdell GS; Richards R; Moriarty H; McCrindle BW
    J Am Coll Cardiol; 2010 Nov; 56(22):1794-802. PubMed ID: 21087706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protamine sulfate for the reversal of enoxaparin associated hemorrhage beyond 12 h.
    Lauer BR; Nelson RA; Adamski JH; Gibbons J; Janko MR; Ravi G; Barcelona RA
    Am J Emerg Med; 2019 Jan; 37(1):174.e5-174.e6. PubMed ID: 30274763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of heparin neutralization by protamine on restenosis after coronary stent implantation.
    Kaneda H; Suzuki J; Hosokawa G; Tanaka S; Hiroe Y; Saito S
    Int J Cardiol; 2005 Oct; 105(1):111-2. PubMed ID: 16207558
    [No Abstract]   [Full Text] [Related]  

  • 15. Nonfatal self-poisoning with LMW heparin and the use of antidote.
    Bjornaas MA; Jacobsen EM; Jacobsen D
    Thromb Res; 2010 Nov; 126(5):e403-5. PubMed ID: 20870279
    [No Abstract]   [Full Text] [Related]  

  • 16. [A means of stopping hemorrhages using preparations with a local pathogenetic action].
    Baluda VP; Sushkevich GN; Pavlovskiĭ DP; Solodovnikova AN; Voĭtkevich LN
    Eksp Khir Anesteziol; 1976; (2):57-9. PubMed ID: 1085248
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibodies against heparin-protamine complexes: Effect and clinical relevance.
    Beckerman Z; Cohen O
    J Thorac Cardiovasc Surg; 2015 Oct; 150(4):974-5. PubMed ID: 26320779
    [No Abstract]   [Full Text] [Related]  

  • 18. In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation.
    Pan M; Suárez de Lezo J; Medina A; Romero M; Hernández E; Segura J; Melian F; Wangüemert F; Landin M; Benítez F; Amat M; Velasco F; Torres A
    Am J Cardiol; 1997 Nov; 80(10):1336-8. PubMed ID: 9388109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of anticoagulant activity of heparin and low molecular weight heparins by poly-l-lysine: A comparative 'in vitro' study versus protamine sulfate.
    Muralidharan-Chari V; Kim J; Mousa SA
    Thromb Res; 2017 Jul; 155():128-130. PubMed ID: 28538195
    [No Abstract]   [Full Text] [Related]  

  • 20. Intraoperative heparin anticoagulation and its reversal.
    Wakefield TW; Stanley JC
    Semin Vasc Surg; 1996 Dec; 9(4):296-302. PubMed ID: 8958606
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.